Astrana Health (ASTH) EBITDA (2010 - 2026)

Astrana Health has disclosed EBITDA across 17 years of filings, most recently posting $28.5 million for Q1 2026.

• EBITDA for Q1 2026 came in at $28.5 million, up 38.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.3 million (down 79.62% YoY), and the FY2025 annual result was $8.3 million, down 90.69% from the prior year.
• EBITDA came in at $28.5 million for Q1 2026 at Astrana Health, up from -$51.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $50.1 million in Q3 2022 to a low of -$51.8 million in Q4 2025.
• The 5-year median for EBITDA is $22.4 million (2023), against an average of $18.5 million.
• Across the five-year window, EBITDA jumped 459.61% in 2022 and sank 7296.39% in 2025, its largest moves.
• Astrana Health's EBITDA stood at $12.6 million in 2022, then slumped by 130.76% to -$3.9 million in 2023, then surged by 118.6% to $720000.0 in 2024, then tumbled by 7296.39% to -$51.8 million in 2025, then soared by 155.06% to $28.5 million in 2026.
• The last three EBITDA figures came in at $28.5 million (Q1 2026), -$51.8 million (Q4 2025), and $19.2 million (Q3 2025), per Business Quant data.